| Autor: |
Maglio A; Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, 84100 Salerno, Italy., Vitale C; Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, 84100 Salerno, Italy., Pelaia C; Department of Health Sciences, University 'Magna Græcia' of Catanzaro, 88100 Catanzaro, Italy., D'Amato M; Department of Respiratory Medicine, Federico II University, 80100 Naples, Italy., Ciampo L; Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, 84100 Salerno, Italy., Sferra E; Department of Respiratory Medicine, Federico II University, 80100 Naples, Italy., Molino A; Department of Respiratory Medicine, Federico II University, 80100 Naples, Italy., Pelaia G; Department of Health Sciences, University 'Magna Græcia' of Catanzaro, 88100 Catanzaro, Italy., Vatrella A; Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, 84100 Salerno, Italy. |
| Abstrakt: |
Add-on biological therapy has proven to be effective in many patients with severe eosinophilic asthma. In this observational multicenter retrospective study, we report the results obtained with mepolizumab and benralizumab in severe asthmatics treated for 12 months in a real-life setting. In these patients, peripheral eosinophil levels, pulmonary function trends, exacerbation rates, systemic corticosteroid use, and symptom control were evaluated during the observation period, to understand which patients met all the criteria in order to be considered in disease remission. The percentage of remittent patients was 30.12% in the mepolizumab-treated subgroup, while in the benralizumab-treated subgroup, patients in complete disease remission were 40%, after 12 months. The results of this study confirm the efficacy of anti-IL-5 biologic drugs in the treatment of severe eosinophilic asthma in a real-life setting. |
